Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Mallinckrodt Plc (NYSE:MNK)

123.96
Delayed Data
As of Jul 31
 +2.26 / +1.86%
Today’s Change
67.18
Today|||52-Week Range
134.26
+25.17%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Other
MARKET CAP
$14.5B

Company Description

Mallinckrodt Plc is a global specialty pharmaceuticals company. It develops, manufactures, markets and distributes both branded and generic specialty pharmaceutical products and medical imaging agents. The company operates its business through two segments: Specialty Pharmaceuticals and Global Medical Imaging. The Specialty Pharmaceuticals segment produces and markets branded pharmaceuticals and biopharmaceuticals, specialty generic pharmaceuticals and active pharmaceutical ingredients consisting of biologics, medicinal opioids, synthetic controlled substances, acetaminophen and other active ingredients. The Global Medical Imaging segment develops, manufactures and markets contrast media and delivery systems and radiopharmaceuticals. Mallinckrodt was founded on January 9, 2013 and is headquartered in Dublin, Ireland.

Contact Information

Mallinckrodt Plc
Damastown Industrial Estate
Dublin Dublin 15
P:(531) 880-8180
Investor Relations:
3533146546650

Employees

Shareholders

Individual stakeholders7.66%
Other institutional53.20%
Mutual fund holders42.88%

Top Executives

Mark C. TrudeauPresident, Chief Executive Officer & Director
Frank ScholzSenior Vice President-Global Operations
Matthew K. HarbaughChief Financial Officer & Senior Vice President
Mario SaltarelliChief Science Officer & Senior Vice President
Steven RomanoChief Scientific Officer & Senior Vice President